# Tosedostat and Cytarabine or Azacitidine in Treating Older Participants With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

> **NCT01636609** · PHASE1 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 18 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- High Risk Myelodysplastic Syndrome

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** Cytarabine
- **DRUG:** Tosedostat

## Key facts

- **NCT ID:** NCT01636609
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-11-20
- **Primary completion:** 2019-07-04
- **Final completion:** 2019-07-04
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** In 2013 the FDA put a temporary hold on the trial and the Phase II portion of this study was cancelled.
- **Last updated:** 2020-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01636609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01636609, "Tosedostat and Cytarabine or Azacitidine in Treating Older Participants With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01636609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*